• +1-646-491-9876
    • +91-20-67278686

    Search

    Hidradenitis Suppurativa-Pipeline Review H2 2017

    Hidradenitis Suppurativa-Pipeline Review H2 2017

    • Report Code ID: RW0001881437
    • Category Life Sciences
    • No. of Pages 97
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Hidradenitis Suppurativa-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hidradenitis Suppurativa-Pipeline Review H2 2017 provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape.

    Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa these deep-seated lumps typically develop where skin rubs together such as the armpits groin between the buttocks and under the breasts.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hidradenitis Suppurativa-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Pre-Registration Phase III Phase II Phase I Preclinical Discovery and Unknown stages are 2 1 4 1 5 1 and 1 respectively.

    Hidradenitis Suppurativa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology) .
    - The pipeline guide reviews pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Hidradenitis Suppurativa-Overview
    Hidradenitis Suppurativa-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Hidradenitis Suppurativa-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Hidradenitis Suppurativa-Companies Involved in Therapeutics Development
    AbbVie Inc
    Celgene Corp
    Coherus BioSciences Inc
    Immunwork Inc
    InflaRx GmbH
    Innovation Pharmaceuticals Inc
    Novartis AG
    Panacea Biotec Ltd
    Sandoz International GmbH
    XBiotech Inc
    Hidradenitis Suppurativa-Drug Profiles
    adalimumab-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    apremilast-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    brilacidin tetrahydrochloride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CJM-112-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IFX-1-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Disrupt Cell Membrane for Hidradenitis Suppurativa-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TE-2232-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Xilonix-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Hidradenitis Suppurativa-Dormant Projects
    Hidradenitis Suppurativa-Discontinued Products
    Hidradenitis Suppurativa-Product Development Milestones
    Featured News & Press Releases
    Jun 12 2017 AbbVie's Humira accepted for use in NHS Scotland
    Feb 22 2017 XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing Application
    Feb 16 2017 XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa
    Jan 04 2017 InflaRx initiates exploratory phase II trial with IFX-1 a first-in-class anti-complement C5a antibody in patients with Hidradenitis Suppurativa
    Nov 14 2016 AbbVie's HUMIRA (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa a Chronic Inflammatory Skin Disease
    Sep 26 2016 AbbVie To present New Data on HUMIRA (adalimumab) at the 25th European Academy of Dermatology and Venereology Congress
    Aug 03 2016 Clinical trial results support adalimumab treatment for painful skin condition
    May 09 2016 Scottish Medicines Consortium (SMC) accepts Humira (adalimumab) as the first approved treatment for the painful chronic skin condition hidradenitis suppurativa for patients in Scotland
    May 04 2016 NICE recommends Humira (adalimumab) as the first approved treatment for skin condition hidradenitis suppurativa in England and Wales
    Mar 02 2016 Abbvie Announces New Dermatology Research From More Than 35 Presentations On Humira (Adalimumab) Long-Term And Real-World Data At The American Academy Of Dermatology 2016 Annual Meeting
    Jan 06 2016 AbbVie HUMIRA (Adalimumab) Receives First and Only Health Canada Approval for Moderate to Severe Hidradenitis Suppurativa
    Oct 05 2015 AbbVie Demonstrates Leadership in Dermatology with 26 Abstracts at the European Academy of Dermatology and Venereology Congress
    Sep 10 2015 Abbvie's Humira (Adalimumab) Receives First And Only U.S. Food And Drug Administration Approval For Moderate To Severe Hidradenitis Suppurativa
    Jul 30 2015 Humira (Adalimumab) Approved By European Commission For Moderate To Severe Hidradenitis Suppurativa
    Jun 26 2015 Abbvie's Humira (Adalimumab) Receives Positive Chmp Opinion To Treat Adult Patients With Active Moderate To Severe Hidradenitis Suppurativa A Chronic Inflammatory Skin Disease
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Hidradenitis Suppurativa H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Hidradenitis Suppurativa-Pipeline by AbbVie Inc H2 2017
    Hidradenitis Suppurativa-Pipeline by Celgene Corp H2 2017
    Hidradenitis Suppurativa-Pipeline by Coherus BioSciences Inc H2 2017
    Hidradenitis Suppurativa-Pipeline by Immunwork Inc H2 2017
    Hidradenitis Suppurativa-Pipeline by InflaRx GmbH H2 2017
    Hidradenitis Suppurativa-Pipeline by Innovation Pharmaceuticals Inc H2 2017
    Hidradenitis Suppurativa-Pipeline by Novartis AG H2 2017
    Hidradenitis Suppurativa-Pipeline by Panacea Biotec Ltd H2 2017
    Hidradenitis Suppurativa-Pipeline by Sandoz International GmbH H2 2017
    Hidradenitis Suppurativa-Pipeline by XBiotech Inc H2 2017
    Hidradenitis Suppurativa-Dormant Projects H2 2017
    Hidradenitis Suppurativa-Discontinued Products H2 2017

    List of Figures

    Number of Products under Development for Hidradenitis Suppurativa H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products by Targets H2 2017
    Number of Products by Stage and Targets H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    AbbVie Inc
    Celgene Corp
    Coherus BioSciences Inc
    Immunwork Inc
    InflaRx GmbH
    Innovation Pharmaceuticals Inc
    Novartis AG
    Panacea Biotec Ltd
    Sandoz International GmbH
    XBiotech Inc

    Request for Sample

    Report Url https://www.reportsweb.com//hidradenitis-suppurativa-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//hidradenitis-suppurativa-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//hidradenitis-suppurativa-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments